Recruiting

Treatment of Supine Hypertension in Autonomic Failure (CPAP)

Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decreases blood pressure in autonomic failure patients with supine hypertension.

ClinicalTrials.gov IDNCT03312556

PhaseNA

Enrollment12

SponsorVanderbilt University Medical Center

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Supine Hypertension, Autonomic Failure

About this study

Interventions

Device: continuous positive airway pressure (CPAP) — Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
Drug: Placebo — Placebo pill or patch. Single dose

Primary outcomes

Supine Systolic Blood Pressure (12 hours)

Eligibility information

Inclusion Criteria: * Patients with autonomic failure and with supine hypertension from all races Exclusion Criteria: * All medical students * Pregnant women * High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction) * History of serious allergies or asthma.

Study locations

Autonomic Dysfunction Center/ Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-30.